<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743639</url>
  </required_header>
  <id_info>
    <org_study_id>UP3758</org_study_id>
    <nct_id>NCT00743639</nct_id>
  </id_info>
  <brief_title>Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy</brief_title>
  <acronym>SDILCM</acronym>
  <official_title>Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiologia do Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Cardiologia do Rio Grande do Sul</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study describes a controlled randomized clinical trial to evaluate the efficacy of bone
      marrow derived stem-cell implants by minithoracotomy in patients with dilated cardiomyopathy
      and cardiac failure class III or NYHA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of the ejection function of the left ventricle</measure>
    <time_frame>twelve months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Interventional</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intramyocardial bone marrow stem cells implantation</intervention_name>
    <description>Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.
Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis made at more than one year and symptomatic at functional class III-IV by the
             New York Heart Association classification (NYHA) despite optimal pharmacologic therapy

          -  Left ventricular ejection fraction (LVEF) less than 35% by echocardiogram

          -  Age below 70 years

          -  Absence of neoplasm

          -  Abscence of hematologic disease or systemic disease

          -  No previous cardiac intervention

        Exclusion Criteria:

          -  Episodes of tachycardia or ventricular fibrillation

          -  Severe or moderated mitral insufficiency

          -  Any other valvulopathies

          -  Previous cardiac surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato AK Kalil, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Cardiology of Rio Grande do Sul / FUC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cardiology of Rio Grande do Sul / FUC</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90620001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <last_update_submitted>August 28, 2008</last_update_submitted>
  <last_update_submitted_qc>August 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>James Fracasso</name_title>
    <organization>Instituto de Cardiologia do Rio Grande do Sul / Fund. Universit. Cardiologia</organization>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <keyword>stem cell</keyword>
  <keyword>cardiac failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

